Understanding psychotic disorders in children with 22q11.2 deletion syndrome
Characterize the Behavioral Prodromes of Psychotic Disorders in Children With 22q11.2DS Aged From 4 to 13 Years Old
This study is trying to find early signs of psychotic disorders in children with 22q11.2 deletion syndrome to better understand how these symptoms develop and possibly help them earlier.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 80 (estimated) |
| Ages | 4 Years to 13 Years |
| Sex | All |
| Sponsor | Hôpital le Vinatier Academic / other |
| Locations | 1 site (Lyon, Auvergne-Rhône-Alpes) |
| Trial ID | NCT04639388 on ClinicalTrials.gov |
What this trial studies
This study investigates the early signs of psychotic disorders in children diagnosed with 22q11.2 deletion syndrome, a genetic condition that significantly increases the risk of developing schizophrenia. The research will utilize neuropsychological testing, questionnaires, and experimental tasks to assess social cognitive processes and behavioral changes in affected children. By identifying prodromal signals, the study aims to enhance understanding of the onset of psychotic symptoms in this population. The findings could provide insights into potential early interventions for these children.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 4 to 13 years who have a diagnosis of 22q11.2 deletion syndrome or no developmental disease.
Not a fit: Patients with a diagnosis of intellectual deficiency or those on medications that could affect brain function may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to earlier identification and intervention strategies for children at risk of developing psychotic disorders.
How similar studies have performed: While there is limited research specifically on prodromal signs in children with 22q11.2 deletion syndrome, studies on related genetic conditions have shown promise in understanding psychotic disorders.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of 22q11.2 deletion syndrome or no developmental disease * Aged from 4 to 13 years old * French language Exclusion Criteria: * Diagnosis of intellectual deficiency according to DSM 5 criteria * Drug prescribed for somatic condition that could influence cerebral functioning
Where this trial is running
Lyon, Auvergne-Rhône-Alpes
- Hopital Vinatier — Lyon, Auvergne-Rhône-Alpes, France (Recruiting)
Study contacts
- Principal investigator: Marie-Noëlle BABINET — Ch Le Vinatier
- Study coordinator: Caroline DEMILY, MD PH
- Email: caroline.demily@ch-le-vinatier.fr
- Phone: 0450915163
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.